Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis

World Journal of Hepatology

Volumn 5, Issue 5, 2013, Pages 275-280

  Yeo, Chong Meng ^a   Chong, Vui Heng ^b   Earnest, Arul ^a   Yang, Wei Lyn ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b RIPAS HOSPITAL   (Brunei Darussalam)

Author keywords

Cirrhosis; Hepatotoxicity; Liver fibrosis; Methotrexate; Risk factors

Indexed keywords

EID: 84879188622     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i5.275     Document Type: Article

References (28)

1. Kuhn A, Ruland V, Patsinakidis N, Luger TA. Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol 2010; 28: S138-S144 [PMID: 21044448]
2. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol 2008; 26: 438-447 [PMID: 18755362 DOI: 10.1016/j.clindermatol. 2007.11.006]
3. Roenigk H. Methotrexate. In: Dubertret L, editor. Psoriasis. Brescia, Italy: ISED, 1994: 162-173
4. Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P, de Lédinghen V. The liver and methotrexate. Gastroenterol Clin Biol 2008; 32: 134-142 [PMID: 18494155 DOI: 10.1016/j.gcb.2007.11.002]
5. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, Hultcrantz R. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118 [PMID: 17399848 DOI: 10.1016/j.jhep.2007.01.024]
6. Berends MA, Snoek J, de Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH, Drenth JP. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006; 24: 805-811 [PMID: 16918884 DOI: 10.1111/j.1365-2036.2006.03047.x]
7. Zachariae H. Have methotrexate-induced liver fibrosis and cirrhosis become rare A matter for reappraisal of routine liver biopsies. Dermatology 2005; 211: 307-308 [PMID: 16286736 DOI: 10.1159/000088497]
8. Roenigk HH, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-485 [PMID: 9520032]
9. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration J Am Acad Dermatol 2000; 42: 531-534 [PMID: 10688735 DOI: 10.1016/S0190-9622(00)90237-8]
10. Christensen E. Is liver biopsy necessary during low-dose methotrexate therapy: A hepatologist's vew. Forum Nord Dermatol Venereol 2004; 10: 9-12
11. Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified Aliment Pharmacol Ther 2004; 19: 391-399 [PMID: 14871278]
12. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-778 [PMID: 8555032 DOI: 10.1111/j.1365-2133.1995. tb02754.x]
13. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837 [PMID: 19389524 DOI: 10.1016/j.jaad.2008.11.906]
14. Park SH, Choe JY, Kim SK. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 2010; 77: 588-592 [PMID: 20471892 DOI: 10.1016/j.jbspin.2010.02.024]
15. Ng LC, Lee YY, Lee CK, Wong SM. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. Int J Dermatol 2013; 52: 102-105 [PMID: 23278617 DOI: 10.1111/j.1365-4632.2011.054.x]
16. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term followup. Can J Gastroenterol 1996; 10: 369-375 [PMID: 9193771]
17. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16: 1395-1401 [PMID: 11851839 DOI: 10.1046/j.1440-1746.2001.02644.x]
18. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16, vii [PMID: 17544968]
19. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013; 10: 307-318 [PMID: 23458891 DOI: 10.1038/ nrgastro.2013.34]
20. Barbero-Villares A, Mendoza Jiménez-Ridruejo J, Taxonera C, López-Sanromán A, Pajares R, Bermejo F, Pérez-Calle JL, Mendoza JL, Algaba A, Moreno-Otero R, Maté J, Gisbert JP. Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47: 575-579 [PMID: 22229701 DOI: 10.3109/0 0365521.2011.647412]
21. Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén E, Gisbert JP, Moreno-Otero R. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011; 137: 637-639 [PMID: 21719043 DOI: 10.1016/j.medcli.2010.12.024]
22. Laharie D, Seneschal J, Schaeverbeke T, Doutre MS, Longy- Boursier M, Pellegrin JL, Chabrun E, Villars S, Zerbib F, de Lédinghen V. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010; 53: 1035-1040 [PMID: 20801541 DOI: 10.1016/j.jhep.2010.04.043]
23. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009; 48: 569-572 [PMID: 19273538 DOI: 10.1093/rheumatology/kep023]
24. Zachariae H, Søgaard H, Heickendorff L. Methotrexateinduced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up. Dermatology 1996; 192: 343-346 [PMID: 8864370]
25. Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, Smith C. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011; 25: 758-764 [PMID: 21198946 DOI: 10.1111/j.1468-3083.2010.03932.x]
26. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M, Hextall JM, Smith CH, Klaber M, Rogers S. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005; 152: 444-450 [PMID: 15787812 DOI: 10.1111/j.1365-2133.2005.06422.x]
27. Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, van de Kerkhof PC, Drenth JP. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-645 [PMID: 17498249 DOI: 10.1111/j.1478-3231.2007.01489.x]
28. Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Naour G, Vaillant JC, Ratziu V, Charlotte F. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol 2012; 56: 541-548 [PMID: 21889468 DOI: 10.1016/ j.jhep.2011.08.007]